Literature DB >> 19451314

Treatment results and late complications of 556 patients with locally advanced nasopharyngeal carcinoma treated with radiotherapy alone.

C Y Chen1, F Han, C Zhao, L X Lu, Y Sun, X F Liu, T X Lu.   

Abstract

The aim of this study was to investigate the outcome in 556 patients with locally advanced nasopharyngeal carcinomas treated by radiation therapy alone. We observed 556 patients with stage T3-4 and N0-3 carcinoma who were treated by conventional radiotherapy alone between January and December 1999. The total dose delivered to the nasopharynx was 66-80 Gy over 6.5-8 weeks and to the neck lymph nodes 60-70 Gy over 6-7 weeks. The 5-year actuarial overall survival rate (OS) reached 66.41%. The OS was higher among stage T3 patients than among stage T4 patients (69.12% vs 58.96%, p = 0.0359). Among patients with stage N0, N1, N2 and N3 disease, the OS was 73.98%, 65.96%, 57.58% and 29.39%, respectively (p = 0.0009). Differences in disease-free survival, locoregional control rate and metastasis-free survival rate among each N stage were statistically significant, although this was not true of differences between stage T3 and T4 disease. Multivariate analysis showed that gender, age, T stage and N stage were significant prognostic factors for 5-year overall survival, disease-free survival, locoregional control and metastasis-free survival. We found that N stage is the dominant prognostic indicator for patients with locally advanced nasopharyngeal carcinoma receiving conventional radiation therapy alone, and that T stage was only a secondary correlative factor.

Entities:  

Mesh:

Year:  2009        PMID: 19451314     DOI: 10.1259/bjr/72813246

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  19 in total

1.  Experience with combination of cisplatin plus gemcitabine chemotherapy and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma.

Authors:  Xiayun He; He Xiayun; Dan Ou; Hongmei Ying; Guopei Zhu; Chaosu Hu; Taifu Liu
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-06-26       Impact factor: 2.503

2.  Analysis of the efficacy of intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in nasopharyngeal carcinoma with involvement of the cervical spine.

Authors:  Hao Jiang; Gengming Wang; Hongwei Song; Hongbo Xu; Yajun Zhang; Yufu Zhou; Hanfei Cai; Shimiao Duan
Journal:  Oncol Lett       Date:  2015-09-03       Impact factor: 2.967

3.  Toxicity of concurrent chemoradiotherapy with cetuximab for locoregionally advanced nasopharyngeal carcinoma.

Authors:  Hui-Xia Feng; Su-Ping Guo; Gui-Rong Li; Wen-Huan Zhong; Liu Chen; Li-Ru Huang; Hui-Ying Qin
Journal:  Med Oncol       Date:  2014-08-15       Impact factor: 3.064

4.  A network meta-analysis for efficacies and toxicities of different therapeutic regimens in the treatment of advanced nasopharyngeal carcinoma.

Authors:  Tingyu Li; Fan Yang; Kening Ma; Lijie Lv
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-01-31       Impact factor: 2.503

5.  Alternative endpoints to the 5-year overall survival and locoregional control for nasopharyngeal carcinoma: A retrospective analysis of 2,450 patients.

Authors:  Chen Chen; Wei Yi; Jin Gao; Xiao-Hui Li; Lu-Jun Shen; Bo-Fei Li; Zi-Wei Tu; Ya-Lan Tao; Chang-Bin Jiang; Yun-Fei Xia
Journal:  Mol Clin Oncol       Date:  2014-02-20

6.  Clinical observation and quality of life in terms of nasal sinusitis after radiotherapy for nasopharyngeal carcinoma: long-term results from different nasal irrigation techniques.

Authors:  H-H Luo; Z-C Fu; H-H Cheng; S-G Liao; D-S Li; L-P Cheng
Journal:  Br J Radiol       Date:  2014-05-12       Impact factor: 3.039

7.  Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma.

Authors:  Xiaoshuang Niu; Chaosu Hu; Lin Kong
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-24       Impact factor: 4.553

8.  Comparison of narrow-band imaging and conventional nasopharyngoscopy for the screening of unaffected members of families with nasopharyngeal carcinoma.

Authors:  Ching-Yin Ho; Kee-Tak Chan; Pen-Yuan Chu
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-01-23       Impact factor: 2.503

9.  Influence of gender and age on the survival of patients with nasopharyngeal carcinoma.

Authors:  Guangli Xiao; Yabing Cao; Xibin Qiu; Weihua Wang; Yufeng Wang
Journal:  BMC Cancer       Date:  2013-05-04       Impact factor: 4.430

10.  Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma.

Authors:  Fen Yang; Xiao-Jun Qian; Wei Qin; Rong Deng; Xiao-Qi Wu; Juan Qin; Gong-Kan Feng; Xiao-Feng Zhu
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.